Hims & Hers Health Surges on Potential Wegovy Partnership with Novo Nordisk
Hims & Hers Health (HIMS) shares rallied 5.65% in pre-market trading following news of discussions with Novo Nordisk (NVO) to offer weight-loss drugs Wegovy and oral Wegovy through its platform. The potential partnership signals a strategic MOVE into the booming weight-loss market, overshadowing mixed Q3 results that saw EPS miss estimates ($0.06 vs. $0.10 expected) while revenue beat forecasts ($599M vs. $580M expected).
No definitive agreement has been reached, and terms may differ from current expectations. Novo Nordisk's oral Wegovy WOULD only be available post-FDA approval. The talks highlight Hims & Hers' push to expand its healthcare offerings beyond prescription medications and online consultations.